文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核病:新药、治疗方案及宿主导向疗法开发的进展与前沿

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
PubMed 文献 · Lancet Infect Dis · 2018-03-23

2016年WHO估计60万例利福平耐药结核,其中49万为耐多药结核,接受推荐方案后生存率不足50%。本文综述了敏感、耐药及潜伏结核的新药与再利用药物、治疗方案和宿主导向疗法的开发管线与临床试验进展。

要点

  • 14种候选药物处于临床开发阶段,其中9种为1期和2期试验中的新药,3种新药处于耐多药结核晚期开发阶段。
  • 正在开展缩短结核疗程、改善耐多药结核治疗转归及预防潜伏感染发病的临床试验。
  • 多种宿主导向疗法和免疫治疗正作为辅助治疗进行研究,旨在缩短疗程、预防永久性肺损伤及改善耐多药结核转归。

核心结论

  • 利益相关方、倡导者和研究者的共同努力正在推进更短程、更有效、更安全且耐受性更好的治疗方案的进一步开发。

研究设计与样本

  • 本文为综述,回顾了针对药物敏感、耐药及潜伏结核的新药和再利用药物、治疗方案及宿主导向疗法的开发管线与前景。

主要发现

  • WHO估计2016年有60万例利福平耐药结核,其中49万为耐多药结核,接受推荐治疗方案后生存率不足50%。
  • 14种候选药物处于临床开发阶段,用于药物敏感、耐药和潜伏结核;其中9种为1期和2期试验中的新药,3种新药处于耐多药结核晚期开发阶段。
  • 贝达喹啉、德拉马尼、普托马尼及其他已上市或再利用药物的临床试验正在开展,旨在缩短结核治疗时长、改善治疗转归和患者依从性并减少毒性效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant (MDR), with less than 50% survival after receiving recommended treatment regimens. Concerted efforts of stakeholders, advocates, and researchers are advancing further development of shorter course, more effective, safer, and better tolerated treatment regimens. We review the developmental pipeline and landscape of new and repurposed tuberculosis drugs, treatment regimens, and host-directed therapies (HDTs) for drug-sensitive and drug-resistant tuberculosis. 14 candidate drugs for drug-susceptible, drug-resistant, and latent tuberculosis are in clinical stages of drug development; nine are novel in phase 1 and 2 trials, and three new drugs are in advanced stages of development for MDR tuberculosis. Specific updates are provided on clinical trials of bedaquiline, delamanid, pretomanid, and other licensed or repurposed drugs that are undergoing investigation, including trials aimed at shortening duration of tuberculosis treatment, improving treatment outcomes and patient adherence, and reducing toxic effects. Ongoing clinical trials for shortening tuberculosis treatment duration, improving treatment outcomes in MDR tuberculosis, and preventing disease in people with latent tuberculosis infection are reviewed. A range of HDTs and immune-based treatments are under investigation as adjunctive therapy for shortening duration of therapy, preventing permanent lung injury, and improving treatment outcomes of MDR tuberculosis. We discuss the HDT development pipeline, ongoing clinical trials, and translational research efforts for adjunct tuberculosis treatment.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018. PMID: 29580819. doi:10.1016/S1473-3099(18)30110-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。